The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.
 
Brian Ball
No Relationships to Disclose
 
Gautam Borthakur
Consulting or Advisory Role - Abbvie; Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Anthony Selwyn Stein
Speakers' Bureau - Amgen
 
Kyle Chan
Employment - BioTheryX
Leadership - BioTheryX
Stock and Other Ownership Interests - BioTheryX
Patents, Royalties, Other Intellectual Property - BioTheryX
 
Dung Luong Thai
Employment - BioTheryX; REMD Biotherapeutics
Leadership - BioTheryX; REMD Biotherapeutics
Stock and Other Ownership Interests - BioTheryX; REMD Biotherapeutics
Consulting or Advisory Role - Amphivena; Arch Oncology; AskGene; Binacea; Five Prime Therapeutics; Gilead Sciences; QR Management; Zenshine
 
Eytan Stein
Stock and Other Ownership Interests - Auron Therapeutics
Consulting or Advisory Role - Abbvie; Agios; Aptose Biosciences; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Calithera Biosciences; CTI BioPharma Corp; Daiichi Sankyo; Debiopharm Group; Foghorn Therapeutics; GEMoaB; Genentech; Genesis Pharma; Gilead Sciences; Immunogen; Janssen; Jazz Pharmaceuticals; Jnana Therapeutics; Menarini; Neoleukin Therapeutics; Novartis; OnCusp Therapeutics; Ono Pharmaceutical; Pinotbio; SERVIER; Syndax
Research Funding - agios (Inst); Bayer (Inst); BioTheryX (Inst); Bristol-Myers Squibb/Celgene (Inst); Cleave Biosciences (Inst); Eisai (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Prelude Therapeutics (Inst); SERVIER (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst)